Ng P C, Wong G W, Lam C W, Lee C H, Fok T F, Wong M Y, Wong W, Chan D C
Department of Pediatrics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
J Clin Endocrinol Metab. 1997 Aug;82(8):2429-32. doi: 10.1210/jcem.82.8.4152.
High dose dexamethasone is frequently used for the treatment of neonatal respiratory conditions and to facilitate weaning from mechanical ventilation in preterm, very low birth weight infants. However, very little is known about the severity, site, and duration of steroid-induced hypothalamic-pituitary-adrenal axis suppression in this category of patients. Twenty-three preterm, very low birth weight infants who received a full 3-week dose-tapering course of dexamethasone were prospectively studied, with a human CRH stimulation test performed at three different times: before the start of steroid treatment (week 0), immediately after the course (week 3), and 4 weeks after stopping dexamethasone (week 7). Plasma ACTH and serum cortisol concentrations were measured at 0 (baseline), 15, 30, and 60 min. Immediately after the steroid course (week 3), both basal and poststimulation plasma ACTH and serum cortisol concentrations were markedly suppressed. The hormone concentrations at 0, 15, 30, and 60 min in week 3 were significantly lower than their corresponding levels in week 0 (P < 0.0001 for both ACTH and cortisol) and week 7 (P < 0.0001 and P < 0.005 for ACTH and cortisol, respectively). In contrast, when the hormone levels in week 7 were compared to their corresponding concentrations in week 0, only the 60 min serum cortisol concentration in week 7 was significantly lower (P = 0.02). The currently used dosage of dexamethasone caused severe pituitary-adrenal suppression immediately after treatment, but substantial recovery of the endocrine axis was observed 4 weeks after discontinuation of therapy. Although the recovery appeared to be earlier with the pituitary center, both pituitary and adrenal glands were capable of mounting a biochemically adequate response to exogenous human CRH stimulation at this stage. Steroid replacement therapy may be desirable at a time of stress in the immediate posttreatment period, but it would seem unnecessary 1 month after stopping dexamethasone treatment.
高剂量地塞米松常用于治疗新生儿呼吸疾病,并促进早产、极低出生体重儿脱离机械通气。然而,对于此类患者中类固醇诱导的下丘脑 - 垂体 - 肾上腺轴抑制的严重程度、部位和持续时间,人们知之甚少。对23名接受了为期3周的地塞米松全疗程剂量递减治疗的早产、极低出生体重儿进行了前瞻性研究,在三个不同时间进行了人促肾上腺皮质激素释放激素(CRH)刺激试验:类固醇治疗开始前(第0周)、疗程结束后立即(第3周)以及停用 地塞米松后4周(第7周)。在0(基线)、15、30和60分钟时测量血浆促肾上腺皮质激素(ACTH)和血清皮质醇浓度。类固醇疗程结束后立即(第3周),基础及刺激后血浆ACTH和血清皮质醇浓度均明显受到抑制。第3周0、15、30和60分钟时的激素浓度显著低于第0周(ACTH和皮质醇均P < 0.0001)和第7周(ACTH为P < 0.0001,皮质醇为P < 0.005)的相应水平。相比之下,当将第7周的激素水平与其在第0周的相应浓度进行比较时,仅第7周60分钟时的血清皮质醇浓度显著较低(P = 0.02)。目前使用的地塞米松剂量在治疗后立即导致严重的垂体 - 肾上腺抑制,但在停药4周后观察到内分泌轴有显著恢复。尽管垂体中心的恢复似乎更早,但此时垂体和肾上腺对外源性人CRH刺激均能够产生生化上足够的反应。在治疗后即刻的应激期可能需要类固醇替代疗法,但在停用 地塞米松治疗1个月后似乎没有必要。